Steven Vold, MD
Glaucoma Specialist · Winter Garden, FLNPI 1891757399
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.7%), speaking fees and other — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Sight Sciences, Inc. at 33.5% of the total. Reporting peaked in 2019 at $125,980 and has fallen 98.6% since, to $1,777 in 2025. Among glaucoma specialist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $1182.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$138K
- AbbVie$67K
- Alcon$62K
- Carl Zeiss Meditec, Inc.$44K
- Rxsight Inc$21K
- Ivantis, Inc$19K
- plus $61K from 20 others
Across 508 payments — averaging $5112.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$541K
- Rxsight Inc$493K
- Carl Zeiss Meditec, Inc.$409K
- AbbVie$298K
- Sight Sciences, Inc.$262K
- Alcon Research LLC$230K
- plus $365K from 5 others
What the payments were for
- Consulting fees$209,26651%
- Speaking & faculty fees$113,60628%
- Grants$3,0001%
- Travel & lodging$3,5371%
- Food & beverage$9,2132%
- Education$18,4054%
- Gifts$1550%
- Other$55,61313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 32 | $138,094 |
| AbbVie(2 entities) | 90 | $67,082 |
| Alcon | 35 | $62,266 |
| Carl Zeiss Meditec, Inc. | 32 | $44,233 |
| Rxsight Inc | 6 | $21,067 |
| Ivantis, Inc | 7 | $19,215 |
| Alcon Research LLC | 7 | $18,200 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $16,917 |
| Carl Zeiss Meditec USA, Inc. | 31 | $13,958 |
| Glaukos Corporation | 35 | $4,153 |
| Carl Zeiss Meditec AG | 2 | $3,269 |
| Bausch Health US, LLC | 2 | $1,600 |
| Aerie Pharmaceuticals, Inc. | 8 | $770 |
| Bausch & Lomb Americas Inc. | 4 | $418 |
| Harrow Eye, LLC | 4 | $380 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $359 |
| Beaver-visitec International, Inc. | 1 | $216 |
| Dompe US, Inc. | 2 | $153 |
| NEW World Medical,inc. | 1 | $144 |
| Amgen(2 entities) | 8 | $140 |
| Lensar, Inc. | 4 | $70 |
| Biotissue Holdings Inc. | 2 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $15 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI$88,600
- Hydrus Microstent$55,613
- OMNI(R) SURGICAL SYSTEM (US)$49,117
- DURYSTA$36,810
- QUATERA 700$21,047
- RXSIGHT CONTACT LENS$20,986
- RXSIGHT INJECTOR CARTRIDGE$20,986
- RXSIGHT INJECTOR HANDPIECE$20,986
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$20,986
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$20,986
- IOLMaster 700$20,270
- ARTEVO 800$19,960
- Hydrus$19,013
- VYZULTA$16,226
- VERACITY SURGICAL$13,600
- XEN$11,902
- AcrySof$10,500
- CALLISTO eye$6,650
- VisuMax$6,636
- LUMIGAN$6,500
How this compares
$412,796 in reported general payments places this provider in the 95th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 42 | $14,317 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $10,855 |
| Prednisolone Acetate | 306 | $8,627 |
| LumiganBimatoprost | 22 | $8,288 |
| VyzultaLatanoprostene Bunod | 18 | $7,960 |
| CombiganBrimonidine Tartrate/Timolol | 22 | $4,431 |
| MoxifloxacinMoxifloxacin Hcl | 192 | $4,187 |
| Bromfenac Sodium | 36 | $3,704 |
| Lotemax SmLoteprednol Etabonate | 13 | $3,261 |
| Difluprednate | 28 | $3,019 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,008 |
| Latanoprost | 322 | $2,848 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 116 | $2,033 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $1,854 |
| ValacyclovirValacyclovir Hcl | 24 | $1,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $16,917 | $17,57855 claims |
| AbbVieLumigan, Combigan | $67,082 | $12,71944 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $770 | $10,85527 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $418 | $7,96018 claims |
| AlconSimbrinza | $62,266 | $3,00815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Winter Garden
- Analisa ArosemenaMiami Beach$438K
- Matthew BrinkPalm Beach Gardens$159K
- David GreenfieldMiami$32K
- Mark WernerDelray Beach$24K
- Dan ArreazaHialeah$9K
- Daniel JewelewiczDelray Beach$9K
- Joah AliancyPort Orange$7K
- Phil AlabataCrestview$7K
- Clinton SheetsHudson$7K
- Norman LevyGainesville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.